Clinical trials
catalyst calendar across sponsors →Studies where CCCC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional
Held by 14 tracked-famous managers (CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, D. E. Shaw & Co., Inc., SUSQUEHANNA INTERNATIONAL GROUP, LLP, RENAISSANCE TECHNOLOGIES LLC, +9 more) · FINRA short interest 11.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaNCT07284758Overall response rate (ORR) per International Myeloma Working Group (IMWG) Response Criteria by an Independent Review Committee (IRC)Open-label · Treatment | Phase 2 | Recruiting | Drug: Cemsidomide, Dexamethasone | Multiple Myeloma, Relapsed/Refractory Multiple Myeloma | 100 | Mar 2030 | ≤ 1,320 d | 2026-08-06 |
| A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma SubjectsNCT07280013Safety and tolerability of cemsidomide in combination with elranatamabOpen-label · Treatment | Phase 1 | Recruiting | Drug: Cemsidomide · Biological: Elranatamab | Multiple Myeloma (MM) | 60 | Dec 2028 | ≤ 865 d | 2026-08-12 |
| Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaNCT04756726Phase 1: Safety and tolerability of cemsidomideNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: cemsidomide, Dexamethasone Oral | Multiple Myeloma, Lymphoma, Non-Hodgkin's | 224 | 2026-09-30 | in 42 d | 2026-03-25 |
| A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid TumorsNCT05668585Frequency and severity of AEs and SAEsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: CFT1946, Trametinib, Cetuximab | Solid Tumors, Melanoma, NSCLC, CRC, ATC | 89 | 2025-11-05actual | — | 2025-11-21 |
| A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null TumorsNCT05355753Frequency and severity of AEs and serious adverse events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: High levels of BRD9 degradation did not result in sufficient efficacy in heavily pre-treated synovial sarcoma and SMARCB1-null solid tumor patients treated with CFT8634 as a single agent. | Drug: CFT8634 | Synovial Sarcoma, Soft Tissue Sarcoma | 49 | 2023-12-19actual | — | 2024-12-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19